Skip to main content
Premium Trial:

Request an Annual Quote

BioSkryb, St. Jude Expand Licensing Deal for Dx Applications of Single-Cell Tech

NEW YORK – Single-cell assay developer BioSkryb announced Monday an exclusive agreement to license technology from St. Jude Children's Research Hospital that it plans to use in a diagnostic test to detect and define populations of cancer cells during treatment.

The deal builds on a previous exclusive licensing agreement for research-based applications of primary template-directed amplification technology. BioSkryb will initially focus on hematologic cancers, followed by the development of similar solutions for solid tumors, the partners said. Financial and other terms of the deal were not disclosed.

BioSkryb's SkrybAmp technology offers whole-genome amplification of single-cells, with the ability to enrich for and capture subsets. The Durham, North Carolina-based firm was cofounded by Stanford University Medical School professor Charles Gawad, who developed PTA while working at St. Jude.

"With this expanded licensing agreement, we hope to use this technology developed by scientists at St. Jude to generate diagnostic solutions that provide real insights to improve cancer treatments," BioSkryb CEO and Cofounder Jay West said in a statement.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.